Investigational Drug Information for simufilam
✉ Email this page to a colleague
What is the development status for investigational drug simufilam?
simufilam is an investigational drug.
There have been 8 clinical trials for simufilam.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2021.
The most common disease conditions in clinical trials are Alzheimer Disease and [disabled in preview]. The leading clinical trial sponsors are Cassava Sciences, Inc., National Institute on Aging (NIA), and Premier Research International LLC.
There are seven US patents protecting this investigational drug and thirty-seven international patents.
Summary for simufilam
US Patents | 7 |
International Patents | 37 |
US Patent Applications | 28 |
WIPO Patent Applications | 7 |
Japanese Patent Applications | 2 |
Clinical Trial Progress | Phase 2 (2021-10-01) |
Vendors | 23 |
Recent Clinical Trials for simufilam
Title | Sponsor | Phase |
---|---|---|
Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects | Cassava Sciences, Inc. | Phase 1 |
Open-label Extension for Phase 3 Clinical Trials of Simufilam | Cassava Sciences, Inc. | Phase 3 |
Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease | Cassava Sciences, Inc. | Phase 2 |
Clinical Trial Summary for simufilam
Top disease conditions for simufilam
Top clinical trial sponsors for simufilam
US Patents for simufilam
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
simufilam | ⤷ Sign Up | Method of inhibiting tau phosphorylation | Pain Therapeutics, Inc. (Austin, TX) | ⤷ Sign Up |
simufilam | ⤷ Sign Up | Alzheimer's disease assay in a living patient | Pain Therapeutics, Inc. (Austin, TX) | ⤷ Sign Up |
simufilam | ⤷ Sign Up | Method for inhibiting growth of cancer cells | Pain Therapeutics (Austin, TX) | ⤷ Sign Up |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for simufilam
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
simufilam | Denmark | DK2882428 | 2032-07-13 | ⤷ Sign Up |
simufilam | European Patent Office | EP2872899 | 2032-07-13 | ⤷ Sign Up |
simufilam | European Patent Office | EP2882428 | 2032-07-13 | ⤷ Sign Up |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |